Portola Pharmaceuticals (NASDAQ:PTLA)‘s stock had its “buy” rating reissued by investment analysts at William Blair in a research report issued on Thursday.
Other analysts also recently issued research reports about the company. Oppenheimer set a $80.00 target price on Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Monday, January 15th. BidaskClub raised Portola Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research note on Thursday, December 21st. Goldman Sachs Group initiated coverage on Portola Pharmaceuticals in a research note on Friday, December 1st. They set a “buy” rating and a $75.00 target price on the stock. ValuEngine raised Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, February 2nd. Finally, Morgan Stanley cut their target price on Portola Pharmaceuticals from $74.00 to $65.00 and set an “overweight” rating on the stock in a research note on Thursday, February 22nd. Two analysts have rated the stock with a sell rating, one has given a hold rating and seven have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and an average price target of $64.90.
Shares of Portola Pharmaceuticals (NASDAQ:PTLA) traded down $2.80 during midday trading on Thursday, hitting $42.32. The company had a trading volume of 1,557,300 shares, compared to its average volume of 1,042,616. The company has a market cap of $2,944.15, a P/E ratio of -7.22 and a beta of 1.18. Portola Pharmaceuticals has a 1-year low of $30.10 and a 1-year high of $67.10. The company has a current ratio of 8.31, a quick ratio of 8.31 and a debt-to-equity ratio of 0.24.
In other Portola Pharmaceuticals news, Director Henry Ward Wolff sold 12,000 shares of Portola Pharmaceuticals stock in a transaction on Friday, December 15th. The stock was sold at an average price of $47.00, for a total transaction of $564,000.00. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. 5.50% of the stock is owned by insiders.
Several hedge funds have recently modified their holdings of PTLA. Oppenheimer Asset Management Inc. increased its position in shares of Portola Pharmaceuticals by 251.2% during the 3rd quarter. Oppenheimer Asset Management Inc. now owns 2,862 shares of the biopharmaceutical company’s stock valued at $155,000 after purchasing an additional 2,047 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank increased its position in shares of Portola Pharmaceuticals by 54.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,219 shares of the biopharmaceutical company’s stock valued at $157,000 after purchasing an additional 1,141 shares during the period. Canada Pension Plan Investment Board acquired a new position in shares of Portola Pharmaceuticals during the 3rd quarter valued at $178,000. Penbrook Management LLC acquired a new position in shares of Portola Pharmaceuticals during the 4th quarter valued at $209,000. Finally, Sei Investments Co. acquired a new position in shares of Portola Pharmaceuticals during the 3rd quarter valued at $217,000. Institutional investors own 86.45% of the company’s stock.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.